ALIPEX est accrédité par Lyonbiopôle

Identity card

Global budget: 25000 k€

Public funding: 10300 k€

Public funders: Oséo / BPI France (except FUI)

Call for projects: ISI Oséo

Year start: 2013

Completed project (2021-06)

Accredited by the French competitiveness cluster Lyonbiopôle

Co-accredited by the French competitiveness cluster Minalogic

Strategic business area: Human Medicines

Application fields: Infectious diseases, Orphan diseases

Technological approaches / Keywords: Biomanufacturing, Drug delivery system, Innovative formulation

Stage of development at the beginning of the project: Preclinical development


  Bpifrance’s commitment to the ALIPEX program is designed to reinforce Alaxia, DTF Medical and their partners. The program combines three breakthrough innovations which could, over time, revolutionize inhalation treatments and facilitate their use at home to deal with the most serious respiratory infections, an important need given the current increase of antibioresistance. The consortium has been granted over €10 M to enable the successful completion of the project and to market the treatment as quickly as possible to fight the effects of Burkholderia cepacia, opportunistic bacteria that invades the lungs of CF patients, for which there is currently no treatment  


  The ALIPEX development program seeks to provide cystic fibrosis (CF) patients with a new-generation inhalation treatment efficient in fighting severe respiratory infections, including those resistant to antibiotics. This treatment, based on 3 major innovations, respectively developed by 2 companies in France’s Rhône-Alpes region – ALAXIA and DTF Medical – benefits from the collaboration with two research laboratories. The ALIPEX development program has been granted support from Bpifrance, as part of its Strategic Industrial Innovation program, asserting the potential of this major therapeutic & technological breakthrough, with possible applications beyond the treatment of this rare disease.

Innovative assets

Innovative assets

  ALX-009, the candidate treatment, is developed by Alaxia as leader of the consortium.  Combination of molecules from the innate defense system, ALX-009 acts on severe respiratory infection. This innovative complementary therapeutic option would respond to a currently unmet medical need. ALX-009, a broad-spectrum antimicrobial treatment has proven to be efficient both in vitro and in vivo when used on bacterial strains with multiple resistance to antibiotics or agglutinated in biofilm.   At the same time, DTF Medical is developing a high-performance nebulizer to optimize the pulmonary deposit of the active substance.    

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à Plus de détails sont disponibles en cliquant ici J'accepte